You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Drug discovery and development are becoming more and more dynamic. New fields of research and innovation are opening up fresh avenues and possibilities. But patents are also expiring, pipelines are running dry, and return on investment is dropping.
While patients struggle at the sidelines, companies and research groups are striving to develop workable business models that can succeed in this changing landscape. Personalized and more specialized medicines are the future - but such research is risky; it lacks the large patient numbers and market pull that have built research momentum - and attracted funding - for many years. New business models must be found.
Open innovation is the way forward - multidisciplinary collaboration between many different stakeholders in pursuit of groundbreaking research. But open innovation needs an independent third party that can bring partners together - driving R&D towards the medicines we critically need.